ArticleFrontiers in public health2021

Economic Evaluation of First-Line Camrelizumab for Advanced Non-small-cell Lung Cancer in China.

Guiyuan Xiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.